# Veru Inc. (VERU)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $48M  
**Price:** $3.26 (+10.51%)

> Veru Inc. is a biopharmaceutical company focused on developing and commercializing novel small‑molecule therapies for cardiometabolic and inflammatory diseases. The company’s lead program centers on enobosarm, an oral selective androgen receptor modulator being evaluated to mitigate loss of muscle mass and function in patients undergoing weight loss treatment with GLP‑1–based therapies, aiming to support higher-quality weight reduction by preserving lean tissue. Veru Inc. is also advancing sabizabulin, an oral microtubule disruptor with broad anti-inflammatory properties under development for chronic inflammation associated with atherosclerotic cardiovascular disease and related conditions. In addition, the company maintains programs in oncology and acute respiratory distress syndrome, with late-stage development assets targeting breast and prostate cancer and viral-related ARDS. Veru Inc. currently generates revenue primarily from the United States, South Africa, and other international markets through its commercial sexual health products, including ENTADFI for benign prostatic hyperplasia and the FC2 Female Condom (Internal Condom). Headquartered in Miami, Florida, Veru Inc. operates as a single business segment within the healthcare and biotechnology industry.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2024 | $17M | $6M | -$36M | -$38M | — |
| 2023 | $16M | $8M | -$94M | -$93M | — |
| 2022 | $39M | $31M | -$83M | -$84M | — |
| 2021 | $61M | $48M | $13M | $7M | — |
| 2020 | $43M | $31M | -$15M | -$19M | — |
| 2019 | $32M | $22M | -$6M | -$12M | — |
| 2018 | $16M | $9M | -$21M | -$24M | — |
| 2017 | $14M | $7M | -$8M | -$7M | — |
| 2016 | $22M | $13M | $3M | $344,725 | — |
| 2015 | $33M | $19M | $7M | $4M | — |
| 2014 | $24M | $13M | $4M | $2M | — |
| 2013 | $31M | $18M | $10M | $14M | — |
| 2012 | $35M | $21M | $11M | $15M | — |
| 2011 | $18,565 | $10M | $3M | $5M | — |
| 2010 | $22M | $13M | $4M | $7M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2024 | $60M | $28M | $32M | $25M | — |
| 2023 | $50M | $30M | $20M | $10M | — |
| 2022 | $135M | $53M | $83M | — | — |
| 2021 | $178M | $26M | $155M | — | — |
| 2020 | $52M | $21M | $30M | — | — |
| 2019 | $54M | $21M | $32M | — | — |
| 2018 | $48M | $19M | $29M | — | $2M |
| 2017 | $55M | $7M | $48M | — | — |
| 2016 | $39M | $5M | $34M | — | — |
| 2015 | $37M | $4M | $33M | $4M | — |
| 2014 | $32M | $4M | $28M | $6M | — |
| 2013 | $35M | $4M | $31M | $9M | — |
| 2012 | $30M | $6M | $24M | $5M | — |
| 2011 | $19M | $3M | $17M | $4M | — |
| 2010 | $18M | $2M | $16M | $3M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$30M | $1,083 | -$30M |
| 2024 | -$22M | $158,322 | -$22M |
| 2023 | -$88M | $665,700 | -$89M |
| 2022 | -$48M | $733,052 | -$48M |
| 2021 | -$16M | $376,649 | -$16M |
| 2020 | -$2M | $105,760 | -$2M |
| 2019 | -$5M | $108,517 | -$6M |
| 2018 | -$12M | $50,654 | -$12M |
| 2017 | $982,888 | $133,486 | $849,402 |
| 2013 | $12M | $302,198 | $11M |
| 2012 | $10M | $718,303 | $10M |
| 2011 | $7M | $46,287 | $7M |
| 2010 | $4M | $51,133 | $4M |
| 2009 | $6M | $2M | $4M |

Source: [CompaniesByCap](https://companiesbycap.com/company/VERU)